These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

354 related articles for article (PubMed ID: 28651211)

  • 1. Effect of insulin degludec versus insulin glargine on glycemic control and daily fasting blood glucose variability in insulin-naïve Japanese patients with type 2 diabetes: I'D GOT trial.
    Aso Y; Suzuki K; Chiba Y; Sato M; Fujita N; Takada Y; Murano S; Kuroda H
    Diabetes Res Clin Pract; 2017 Aug; 130():237-243. PubMed ID: 28651211
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Multinational, Randomized, Open-label, Treat-to-Target Trial Comparing Insulin Degludec and Insulin Glargine in Insulin-Naïve Patients with Type 2 Diabetes Mellitus.
    Pan C; Gross JL; Yang W; Lv X; Sun L; Hansen CT; Xu H; Wagner R
    Drugs R D; 2016 Jun; 16(2):239-49. PubMed ID: 27098525
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized crossover study of the efficacy and safety of switching from insulin glargine to insulin degludec in children with type 1 diabetes.
    Urakami T; Mine Y; Aoki M; Okuno M; Suzuki J
    Endocr J; 2017 Feb; 64(2):133-140. PubMed ID: 27746408
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low-volume insulin degludec 200 units/ml once daily improves glycemic control similarly to insulin glargine with a low risk of hypoglycemia in insulin-naive patients with type 2 diabetes: a 26-week, randomized, controlled, multinational, treat-to-target trial: the BEGIN LOW VOLUME trial.
    Gough SC; Bhargava A; Jain R; Mersebach H; Rasmussen S; Bergenstal RM
    Diabetes Care; 2013 Sep; 36(9):2536-42. PubMed ID: 23715753
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of insulin degludec three times a week versus insulin glargine once a day in insulin-naive patients with type 2 diabetes: results of two phase 3, 26 week, randomised, open-label, treat-to-target, non-inferiority trials.
    Zinman B; DeVries JH; Bode B; Russell-Jones D; Leiter LA; Moses A; Johansen T; Ratner R;
    Lancet Diabetes Endocrinol; 2013 Oct; 1(2):123-31. PubMed ID: 24622318
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reduced risk of hypoglycemia with insulin degludec versus insulin glargine in patients with type 2 diabetes requiring high doses of basal insulin: a meta-analysis of 5 randomized begin trials.
    Rodbard HW; Gough S; Lane W; Korsholm L; Bretler DM; Handelsman Y
    Endocr Pract; 2014 Apr; 20(4):285-92. PubMed ID: 24246344
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The efficacy and safety of insulin degludec given in variable once-daily dosing intervals compared with insulin glargine and insulin degludec dosed at the same time daily: a 26-week, randomized, open-label, parallel-group, treat-to-target trial in individuals with type 2 diabetes.
    Meneghini L; Atkin SL; Gough SC; Raz I; Blonde L; Shestakova M; Bain S; Johansen T; Begtrup K; Birkeland KI;
    Diabetes Care; 2013 Apr; 36(4):858-64. PubMed ID: 23340894
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Day-to-Day and Within-Day Variability in Glucose-Lowering Effect Between Insulin Degludec and Insulin Glargine (100 U/mL and 300 U/mL): A Comparison Across Studies.
    Heise T; Kaplan K; Haahr HL
    J Diabetes Sci Technol; 2018 Mar; 12(2):356-363. PubMed ID: 28946756
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Insulin degludec results in lower rates of nocturnal hypoglycaemia and fasting plasma glucose vs. insulin glargine: A meta-analysis of seven clinical trials.
    Russell-Jones D; Gall MA; Niemeyer M; Diamant M; Del Prato S
    Nutr Metab Cardiovasc Dis; 2015 Oct; 25(10):898-905. PubMed ID: 26232910
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of insulin degludec and insulin glargine on day-to-day fasting plasma glucose variability in individuals with type 1 diabetes: a multicentre, randomised, crossover study.
    Nakamura T; Sakaguchi K; So A; Nakajima S; Takabe M; Komada H; Okuno Y; Hirota Y; Nakamura T; Iida K; Kajikawa M; Nagata M; Ogawa W; Seino S
    Diabetologia; 2015 Sep; 58(9):2013-9. PubMed ID: 26044206
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The efficacy and safety of insulin degludec versus insulin glargine in insulin-naive subjects with type 2 diabetes: results of a Chinese cohort from a multinational randomized controlled trial].
    Mu YM; Guo LX; Li L; Li YM; Xu XJ; Li QM; Xu MT; Zhu LY; Yuan GY; Liu Y; Xu C; Wang ZJ; Shen FX; Luo Y; Liu JY; Li QF; Wang WH; Lai XY; Xu HF; Pan CY
    Zhonghua Nei Ke Za Zhi; 2017 Sep; 56(9):660-666. PubMed ID: 28870034
    [No Abstract]   [Full Text] [Related]  

  • 12. Insulin degludec: Lower day-to-day and within-day variability in pharmacodynamic response compared with insulin glargine 300 U/mL in type 1 diabetes.
    Heise T; Nørskov M; Nosek L; Kaplan K; Famulla S; Haahr HL
    Diabetes Obes Metab; 2017 Jul; 19(7):1032-1039. PubMed ID: 28295934
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Insulin Degludec Versus Insulin Glargine on Glycemic Variability in Diabetic Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    Yang Y; Long C; Li T; Chen Q
    Front Endocrinol (Lausanne); 2022; 13():890090. PubMed ID: 35721710
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of insulin degludec U100 and insulin glargine U100 in combination with meal-time bolus insulin in hospitalized patients with type 2 diabetes: an open-label, randomized controlled study.
    Suzuki J; Yamakawa T; Oba M; Nagakura J; Shigematsu E; Tamura H; Takahashi K; Okamoto Y; Sakamoto R; Shinoda M; Takano T; Kadonosono K; Terauchi Y
    Endocr J; 2019 Nov; 66(11):971-982. PubMed ID: 31270291
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical perspectives from the BEGIN and EDITION programmes: Trial-level meta-analyses outcomes with either degludec or glargine 300U/mL vs glargine 100U/mL in T2DM.
    Roussel R; Ritzel R; Boëlle-Le Corfec E; Balkau B; Rosenstock J
    Diabetes Metab; 2018 Nov; 44(5):402-409. PubMed ID: 29548798
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The differences between insulin glargine U300 and insulin degludec U100 in impact on the glycaemic variability, arterial stiffness and the lipid profiles in insulin naïve patients suffering from type two diabetes mellitus - outcomes from cross-over open-label randomized trial.
    Cindro PV; Krnić M; Modun D; Smajić B; Vuković J
    BMC Endocr Disord; 2021 Apr; 21(1):86. PubMed ID: 33926446
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of insulin degludec and insulin glargine U300 on glycaemic stability in individuals with type 1 diabetes: A multicentre, randomized controlled crossover study.
    Miura H; Sakaguchi K; Otowa-Suematsu N; Yamada T; So A; Komada H; Okada Y; Hirota Y; Tamori Y; Ogawa W
    Diabetes Obes Metab; 2020 Dec; 22(12):2356-2363. PubMed ID: 32744395
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hypoglycaemia risk with insulin degludec compared with insulin glargine in type 2 and type 1 diabetes: a pre-planned meta-analysis of phase 3 trials.
    Ratner RE; Gough SC; Mathieu C; Del Prato S; Bode B; Mersebach H; Endahl L; Zinman B
    Diabetes Obes Metab; 2013 Feb; 15(2):175-84. PubMed ID: 23130654
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of insulin degludec in a flexible dosing regimen vs insulin glargine in patients with type 1 diabetes (BEGIN: Flex T1): a 26-week randomized, treat-to-target trial with a 26-week extension.
    Mathieu C; Hollander P; Miranda-Palma B; Cooper J; Franek E; Russell-Jones D; Larsen J; Tamer SC; Bain SC;
    J Clin Endocrinol Metab; 2013 Mar; 98(3):1154-62. PubMed ID: 23393185
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of the pharmacokinetic and pharmacodynamic profiles of insulin degludec and insulin glargine.
    Heise T; Hövelmann U; Nosek L; Hermanski L; Bøttcher SG; Haahr H
    Expert Opin Drug Metab Toxicol; 2015; 11(8):1193-201. PubMed ID: 26086190
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.